Login to Your Account

Galapagos sees GLPG-1690 bloom in Flora IPF trial

By Michael Fitzhugh
Staff Writer

Thursday, August 10, 2017

Galapagos NV's autotaxin inhibitor, GLPG-1690, halted worsening lung function in adults with idiopathic pulmonary fibrosis during the 12 weeks of a small phase IIa trial, setting the stage for it to quickly move on to late-stage testing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription